학술논문
Cardiac sarcoidosis and giant cell myocarditis after COVID‐19 infection
Document Type
Report
Author
Source
ESC Heart Failure. December 2022, Vol. 9 Issue 6, p4298, 6 p.
Subject
Language
English
Abstract
Introduction Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. Here, we describe the clinical presentation and management of four cases with granulomatous myocarditis [sarcoidosis or giant cell myocarditis [...]
: Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID‐19 infection might suggest that COVID‐19 could be a trigger for granulomatous myocarditis.
: Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID‐19 infection might suggest that COVID‐19 could be a trigger for granulomatous myocarditis.